Applying Efficacy and Safety Science to Develop Individualized Treatment Plans for Patients With Multiple Sclerosis


Program Dates: June 28, 2019 - July 14, 2020
Credits: 1.0 AMA PRA Category 1 Credit™; 1.0 CNE Contact Hour; 1.0 CPE Contact Hour (0.10 CEU)


3d illustration of nerve cells. Affected Human nervous system, concept for Neurological Diseases, tumors and brain surgery.

Applying Efficacy and Safety Science to Develop Individualized Treatment Plans for Patients With Multiple Sclerosis

Program Overview

Advances in the science and clinical trial data for the treatment of patients with multiple sclerosis (MS) continue to evolve at a rapid pace. This continuing education program, derived from content presented at the 2019 Consortium of Multiple Sclerosis Centers Meeting, will bring healthcare professionals up-to-date on recent treatment and management strategies in MS, including S1P based therapies. Emphasis will be placed on clinical decision making and best practices for utilizing personalized medicine to improve outcomes in patients with multiple sclerosis. This activity will address the important role of the interprofessional team in delivering optimal comprehensive care to patients with multiple sclerosis.

Target Audience

Neurologists, physicians, physician assistants, pharmacists, nurse practitioners, nurses, physical therapists and other healthcare professionals involved in the management of patients with multiple sclerosis

Learning Objectives

  1. Update knowledge to the most current efficacy and safety data for MS therapies
  2. Develop MS therapeutic treatment plans on an individualized patient basis
  3. Integrate the interprofessional team to optimize patient education and adherence to therapy

Faculty

FDL Summer 2015-2Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

 

 

Ben-ZachariaAliza Ben-Zacharia, DrNP, ANP-BC
Neurology Teaching Assistant
Icahn School of Medicine at Mount Sinai
Corinne Goldsmith Dickinson Center for MS
The Mount Sinai Medical Center
New York, New York

 

 

BERGER_HEADSHOTJoseph R. Berger, MD
Associate Chief of the MS Division
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

 

 

 

KriegerStephen Krieger, MD
Associate Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Director, Neurology Residency Program
Icahn School of Medicine at Mount Sinai
New York, New York

 

 

 MarkowitzClyde Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor of Neurology
University of Pennsylvania
Philadelphia, Pennsylvania

 

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

FacultyRelationship Identified With:
Fred D. Lublin, MDConsultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals; Apitope; Atara Biotherapeutics; Biogen; Brainstorm Cell Therapeutics; Celgene Corporation; EMD Serono; Forward Pharma; Genentech, Inc.; Genzyme Corporation; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; MedDay Pharmaceuticals; Mapi Pharma; MedImmune; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma; Receptos, Inc.; Regeneron; Roche; Sanofi; Teva Pharmaceuticals; TG TherapeuticsSpeaker’s Bureau: Sanofi
Aliza Ben-Zacharia, DrNP, ANP-BCConsultant/Advisor: Biogen; Celgene Corporation; EMD Serono; Genentech, Inc.; Genzyme Corporation; Novartis Pharmaceuticals CorporationResearch/Grant Support: Biogen
Joseph R. Berger, MDConsultant/Advisor: Amgen Inc.; Biogen; Celgene Corporation; EMD Serono;  Encycle Corporation; Excision Bio Therapeutics; Genzyme Corporation; Inhibikase Therapeutics; Novartis Pharmaceuticals Corporation; Sanofi; Shire; Takeda Pharmaceutical Company LimitedResearch/Grant Support: Biogen
Stephen Krieger, MDConsultant/Advisor: BiogenEMD Serono; Genentech, Inc.; Genzyme Corporation; Mallinckrodt; MedDay Pharmaceuticals; Novartis Pharmaceuticals Corporation; Teva Pharmaceuticals; TG TherapeuticsSpeaker’s Bureau: Biogen; Novartis Pharmaceuticals Corporation

Clyde Markowitz, MD

Consultant/Advisor: Actelion Pharmaceuticals; Alexion; Biogen; Bayer AG; Celgene Corporation; EMD Serono; Genentech, Inc.; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Roche; Sanofi; Teva Pharmaceuticals

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Joseph Feick, PharmD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (Provider number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE contact hour (0.10 CEU) of continuing pharmacy education credit (UAN # JA4008190-0000-19-004-L01-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Celgene Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web